Literature DB >> 26787695

Mutations in gyrA and gyrB among Fluoroquinolone- and Multidrug-Resistant Mycobacterium tuberculosis Isolates.

Jung-Yien Chien1, Wei-Yih Chiu1, Shun-Tien Chien2, Chia-Jung Chiang2, Chong-Jen Yu3, Po-Ren Hsueh4.   

Abstract

In order to correlate the mutations inside the entiregyrAandgyrBgenes with the level of resistance to ofloxacin (OFX) and moxifloxacin (MFX) in isolates of multidrug-resistantMycobacterium tuberculosis(MDR-TB), a total of 111 isolates were categorized into OFX-susceptible (MIC, ≤2 μg/ml) and low-level (MIC, 4 to 8 μg/ml) and high-level (MIC, ≥16 μg/ml) OFX-resistant isolates and MFX-susceptible (MIC, ≤0.5 μg/ml) and low-level (MIC, 1 to 2 μg/ml) and high-level (MIC, ≥4 μg/ml) MFX-resistant isolates. Resistance-associated mutations inside thegyrAgene were found in 30.2% of OFX-susceptible and 72.5% and 72.2% of low-level and high-level OFX-resistant isolates and in 28.6% of MFX-susceptible and 58.1% and 83.9% of low-level and high-level MFX-resistant isolates. Compared with OFX-susceptible isolates, low-level and high-level OFX-resistant isolates had a significantly higher prevalence of mutations atgyrAcodons 88 to 94 (17.0%, 65.0%, and 72.2%, respectively;P< 0.001) and a higher prevalence of thegyrBG512R mutation (0.0%, 2.5%, and 16.7%, respectively;P= 0.006). Similarly, compared with MFX-susceptible isolates, low-level and high-level MFX-resistant isolates had a significantly higher prevalence of mutations atgyrAcodons 88 to 94 (14.3%, 51.6%, and 80.6%, respectively;P< 0.001) as well as a higher prevalence of thegyrBG512R mutation (0.0%, 0.0%, and 12.9%, respectively;P= 0.011). D94G and D94N mutations ingyrAand the G512R mutation ingyrBwere correlated with high-level MFX resistance, while the D94A mutation was associated with low-level MFX resistance. The prevalence of mutations atgyrAcodons 88 to 94 and thegyrBG512R mutation were higher among fluoroquinolone (FQ)-susceptible East Asian (Beijing) and Indo-Oceanic strains than they were among Euro-American strains, implying that molecular techniques to detect FQ resistance may be less specific in areas with a high prevalence of East Asian (Beijing) and Indo-Oceanic strains.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26787695      PMCID: PMC4808166          DOI: 10.1128/AAC.01049-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  Mutation characterization of gyrA and gyrB genes in levofloxacin-resistant Mycobacterium tuberculosis clinical isolates from Guangdong Province in China.

Authors:  Xiaomao Yin; Zhaoxian Yu
Journal:  J Infect       Date:  2010-05-07       Impact factor: 6.072

2.  High proportion of fluoroquinolone-resistant Mycobacterium tuberculosis isolates with novel gyrase polymorphisms and a gyrA region associated with fluoroquinolone susceptibility.

Authors:  Rose Devasia; Amondrea Blackman; Svetlana Eden; Haijing Li; Fernanda Maruri; Ayumi Shintani; Charles Alexander; Anne Kaiga; Charles W Stratton; Jon Warkentin; Yi-Wei Tang; Timothy R Sterling
Journal:  J Clin Microbiol       Date:  2011-12-21       Impact factor: 5.948

3.  Correlating Minimum Inhibitory Concentrations of ofloxacin and moxifloxacin with gyrA mutations using the genotype MTBDRsl assay.

Authors:  Priti Kambli; Kanchan Ajbani; Meeta Sadani; Chaitali Nikam; Anjali Shetty; Zarir Udwadia; Timothy C Rodwell; Antonino Catanzaro; Camilla Rodrigues
Journal:  Tuberculosis (Edinb)       Date:  2014-12-03       Impact factor: 3.131

4.  Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacterium tuberculosis to levofloxacin, moxifloxacin and gatifloxacin.

Authors:  Elena Yu Nosova; Anastasia A Bukatina; Yulia D Isaeva; Marina V Makarova; Ksenia Yu Galkina; Arkadyi M Moroz
Journal:  J Med Microbiol       Date:  2012-09-27       Impact factor: 2.472

5.  Proposal for standardization of optimized mycobacterial interspersed repetitive unit-variable-number tandem repeat typing of Mycobacterium tuberculosis.

Authors:  Philip Supply; Caroline Allix; Sarah Lesjean; Mara Cardoso-Oelemann; Sabine Rüsch-Gerdes; Eve Willery; Evgueni Savine; Petra de Haas; Henk van Deutekom; Solvig Roring; Pablo Bifani; Natalia Kurepina; Barry Kreiswirth; Christophe Sola; Nalin Rastogi; Vincent Vatin; Maria Cristina Gutierrez; Maryse Fauville; Stefan Niemann; Robin Skuce; Kristin Kremer; Camille Locht; Dick van Soolingen
Journal:  J Clin Microbiol       Date:  2006-09-27       Impact factor: 5.948

6.  gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis.

Authors:  Frederick A Sirgel; Robin M Warren; Elizabeth M Streicher; Thomas C Victor; Paul D van Helden; Erik C Böttger
Journal:  J Antimicrob Chemother       Date:  2012-02-22       Impact factor: 5.790

7.  Characterization of multiple and extensively drug resistant Mycobacterium tuberculosis isolates with different ofloxacin-resistance levels.

Authors:  Ekaterina Chernyaeva; Ekaterina Fedorova; Galina Zhemkova; Yuriy Korneev; Andrei Kozlov
Journal:  Tuberculosis (Edinb)       Date:  2013-03-13       Impact factor: 3.131

8.  Extensively drug-resistant Mycobacterium tuberculosis during a trend of decreasing drug resistance from 2000 through 2006 at a Medical Center in Taiwan.

Authors:  Chih-Cheng Lai; Che-Kim Tan; Yu-Tsung Huang; Chien-Hong Chou; Chien-Ching Hung; Pan-Chyr Yang; Kwen-Tay Luh; Po-Ren Hsueh
Journal:  Clin Infect Dis       Date:  2008-10-01       Impact factor: 9.079

9.  Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure.

Authors:  Jann-Yuan Wang; Li-Na Lee; Hsin-Chih Lai; Shu-Kuan Wang; I-Shiow Jan; Chong-Jen Yu; Po-Ren Hsueh; Pan-Chyr Yang
Journal:  J Antimicrob Chemother       Date:  2007-04-05       Impact factor: 5.790

10.  Association of gyrA/B mutations and resistance levels to fluoroquinolones in clinical isolates of Mycobacterium tuberculosis.

Authors:  Jing Li; Xu Gao; Tao Luo; Jie Wu; Gang Sun; Qingyun Liu; Yuan Jiang; Yangyi Zhang; Jian Mei; Qian Gao
Journal:  Emerg Microbes Infect       Date:  2014-03-12       Impact factor: 7.163

View more
  18 in total

Review 1.  Revisiting the mutant prevention concentration to guide dosing in childhood tuberculosis.

Authors:  Devan Jaganath; H Simon Schaaf; Peter R Donald
Journal:  J Antimicrob Chemother       Date:  2017-07-01       Impact factor: 5.790

2.  Genetic Diversity of Multi- and Extensively Drug-Resistant Mycobacterium tuberculosis Isolates in the Capital of Iran, Revealed by Whole-Genome Sequencing.

Authors:  Farzam Vaziri; Thomas A Kohl; Hasan Ghajavand; Mansour Kargarpour Kamakoli; Matthias Merker; Shima Hadifar; Sharareh Khanipour; Abolfazl Fateh; Morteza Masoumi; Seyed Davar Siadat; Stefan Niemann
Journal:  J Clin Microbiol       Date:  2019-01-02       Impact factor: 5.948

3.  Limited Effect of Later-Generation Fluoroquinolones in the Treatment of Ofloxacin-Resistant and Moxifloxacin-Susceptible Multidrug-Resistant Tuberculosis.

Authors:  Hyun Lee; Soohyun Ahn; Na Young Hwang; Kyeongman Jeon; O Jung Kwon; Hee Jae Huh; Nam Yong Lee; Chang-Ki Kim; Won-Jung Koh
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

4.  Nε- and O-Acetylation in Mycobacterium tuberculosis Lineage 7 and Lineage 4 Strains: Proteins Involved in Bioenergetics, Virulence, and Antimicrobial Resistance Are Acetylated.

Authors:  Alemayehu Godana Birhanu; Solomon Abebe Yimer; Carol Holm-Hansen; Gunnstein Norheim; Abraham Aseffa; Markos Abebe; Tone Tønjum
Journal:  J Proteome Res       Date:  2017-10-04       Impact factor: 4.466

5.  Xpert MTB/XDR: a 10-Color Reflex Assay Suitable for Point-of-Care Settings To Detect Isoniazid, Fluoroquinolone, and Second-Line-Injectable-Drug Resistance Directly from Mycobacterium tuberculosis-Positive Sputum.

Authors:  Yuan Cao; Heta Parmar; David Alland; Soumitesh Chakravorty; Rajiv L Gaur; Deanna Lieu; Shobana Raghunath; Nova Via; Simone Battaglia; Daniela M Cirillo; Claudia Denkinger; Sophia Georghiou; Robert Kwiatkowski; David Persing
Journal:  J Clin Microbiol       Date:  2021-02-18       Impact factor: 5.948

6.  In Vitro Activity and MIC of Sitafloxacin against Multidrug-Resistant and Extensively Drug-Resistant Mycobacterium tuberculosis Isolated in Thailand.

Authors:  Manoon Leechawengwongs; Therdsak Prammananan; Sarinya Jaitrong; Pamaree Billamas; Nampueng Makhao; Nongnard Thamnongdee; Arirat Thanormchat; Arisa Phurattanakornkul; Somcharn Rattanarangsee; Chate Ratanajaraya; Areeya Disratthakit; Angkana Chaiprasert
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

7.  Mutations in gyrA and gyrB in Moxifloxacin-Resistant Mycobacterium avium Complex and Mycobacterium abscessus Complex Clinical Isolates.

Authors:  Su-Young Kim; Byung Woo Jhun; Seong Mi Moon; Sun Hye Shin; Kyeongman Jeon; O Jung Kwon; In Young Yoo; Hee Jae Huh; Chang-Seok Ki; Nam Yong Lee; Sung Jae Shin; Charles L Daley; Gee Young Suh; Won-Jung Koh
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

8.  Resistance-Conferring Mutations on Whole-Genome Sequencing of Fluoroquinolone-resistant and -Susceptible Mycobacterium tuberculosis Isolates: A Proposed Threshold for Identifying Resistance.

Authors:  Fernanda Maruri; Yan Guo; Amondrea Blackman; Yuri F van der Heijden; Peter F Rebeiro; Timothy R Sterling
Journal:  Clin Infect Dis       Date:  2021-06-01       Impact factor: 9.079

9.  Single-nucleotide polymorphisms related to fluoroquinolone and aminoglycoside resistance in Mycobacterium avium isolates.

Authors:  Hui Pang; Kanglin Wan; Lin Wei
Journal:  Infect Drug Resist       Date:  2018-04-09       Impact factor: 4.003

10.  Phenotypic and genotypic characterization of levofloxacin- and moxifloxacin-resistant Mycobacterium tuberculosis clinical isolates in southern China.

Authors:  H M Adnan Hameed; Yaoju Tan; Md Mahmudul Islam; Lingmin Guo; Chiranjibi Chhotaray; Shuai Wang; Zhiyong Liu; Yamin Gao; Shouyong Tan; Wing Wai Yew; Nanshan Zhong; Jianxiong Liu; Tianyu Zhang
Journal:  J Thorac Dis       Date:  2019-11       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.